Unregulated diagnostic tests are bleeding patients in Kashmir
The cost of falling ill in Kashmir is becoming unbearably high, not just in the operation theatre or private ward. It is in the laboratory. From a simple blood test to an MRI scan, diagnostic investigations have turned into a lucrative business, largely shielded from scrutiny and free from any meaningful price regulation. As a result, ordinary patients are paying the price, often literally with borrowed money and future earnings. Across the Valley, the story is disturbingly similar. A doctor’s prescription for a few routine tests can easily add up to several thousand rupees. For a daily wager, a shopkeeper, a low‑paid employee, this is not just a medical expense, it is an economic shock. Families sell valuables, cut down on food, or postpone children’s education to fund a series of tests that the system has made non‑negotiable but unaffordable. Many, unable to cope, simply skip or delay essential diagnostics, turning curable ailments into chronic disease and preventable complications. What makes this crisis more alarming is the complete absence of a rational pricing framework. Private diagnostic centres and labs charge what they wish, with huge disparities in rates for the same test within the same town. There is no standardised tariff, no publicly notified ceiling, and no effective watchdog. Patients walk in without information and walk out with bills they never anticipated. Public hospitals, where tests are cheaper, remain overburdened, under‑staffed, and often short of reagents and functioning machines, pushing even the poor towards the private sector. Successive administrations have spoken of affordability and universal access, yet the diagnostic sector has been allowed to grow as an unregulated marketplace. This abdication must end. The government can no longer look away while a critical component of healthcare operates in a policy vacuum. It must immediately commission a comprehensive review of diagnostic pricing in J&K, fix region‑specific, realistic rate caps for common tests, and enforce transparency in billing. Mandatory display of approved rates, periodic audits, strict action against overcharging, and expansion and upgradation of diagnostic services in public hospitals are no longer optional reforms; they are urgent necessities. In an economically fragile society, healthcare cannot be allowed to become a profit carnival. Until diagnostic tests are brought under firm regulation and oversight, the promise of affordable healthcare in Kashmir will remain hollow rhetoric, and our laboratories will continue to echo with the silent suffering of those who cannot pay.